Minimal residual disease status predicts outcomes in patients with follicular lymphoma treated with chemoimmunotherapy on the SWOG S0016 trial.

Danilov AV; Li H; Shadman M; Rimsza L; Zebari A; Smith SM; LeBlanc M; Friedberg JW; Carlson C; Song JY

doi:10.3324/haematol.2025.288057

← 뒤로

Minimal residual disease status predicts outcomes in patients with follicular lymphoma treated with chemoimmunotherapy on the SWOG S0016 trial.

0/5 보강

Haematologica 2025 Vol.110(12) p. 3145-3149

Danilov AV, Li H, Shadman M, Rimsza L, Zebari A, Smith SM, LeBlanc M, Friedberg JW, Carlson C, Song JY

PMC 전문 ↗ 원문 ↗ DOI ↗ BibTeX ↓ RIS ↓

이 논문을 인용하기

BibTeX ↓ RIS ↓

APA Danilov AV, Li H, et al. (2025). Minimal residual disease status predicts outcomes in patients with follicular lymphoma treated with chemoimmunotherapy on the SWOG S0016 trial.. Haematologica, 110(12), 3145-3149. https://doi.org/10.3324/haematol.2025.288057

MLA Danilov AV, et al.. "Minimal residual disease status predicts outcomes in patients with follicular lymphoma treated with chemoimmunotherapy on the SWOG S0016 trial.." Haematologica, vol. 110, no. 12, 2025, pp. 3145-3149.

PMID 40605713

DOI 10.3324/haematol.2025.288057

같은 제1저자의 인용 많은 논문 (1)

Clinical strategies for lymphoma management: Recommendations from the Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Consensus Conference 2025.
Cancer 2026